Key result
EHRA Type 1 and Type 2 VHD show distinct thromboembolic and bleeding risks despite underused anticoagulation.
Why the study?
The risks of thromboembolism and bleeding in patients with AF and valvular heart disease are sparsely described.
What are the risks of thromboembolism and major bleeding in non-anticoagulated and anticoagulated patients with atrial fibrillation and valvular heart disease according to the EHRA classification?
Cohort (n=28,770)
Yes
What are the risks of thromboembolism and major bleeding in non-anticoagulated and anticoagulated patients with atrial fibrillation and valvular heart disease according to the EHRA classification?
Answers are grounded in this paper and cite their sources.
This descriptive study characterizes the incidence of thromboembolic and bleeding events across EHRA classifications for VHD in AF, highlighting a substantial underuse of anticoagulation in high-risk patients.
Aims The risks of thromboembolism and bleeding in patients with atrial fibrillation (AF) and valvular heart disease (VHD) are sparsely described. We described the risk of events in non-anticoagulated and anticoagulated patients with AF and VHD according to the evaluated heart valves, rheumatic or artificial valve classification (EHRA classification), EHRA Type 1 and Type 2 VHD, and within subgroups of EHRA Type 1 and Type 2 VHD. Methods and Results Cohort study of AF patients with coexisting VHD, identified in nationwide Danish registries from 2000 to 2018. Risk of thromboembolism and bleeding after 1 year of follow-up were calculated in each group. We identified 28 770 incident AF patients with VHD. Not surprisingly, we observed the highest risks of thromboembolism in the non-anticoagulated AF patients with EHRA Type 1 and Type 2 VHD (4.9% vs 2.6% and 3.2% vs 1.9%) and the highest risks of bleeding in the anticoagulated AF patients with EHRA Type 1 and Type 2 VHD (6.6% vs 4.3% and 6.1% vs 4.9%). However, within the subgroups of AF patients with EHRA Type 1 and Type 2 VHD, we observed a large proportion of non-anticoagulated patients (32.9%-49.2%), despite a CHA2DS2-VASc score of 2≤ in the majority of these patients (81.9%-95.6%). Conclusions When using data reflecting contemporary clinical practice, we observed markedly different risks of thromboembolism and bleeding in EHRA Type 1 and Type 2 VHD. Additionally, we observed a potential underuse of oral anticoagulation within the subgroups of AF patients with EHRA Type 1 and Type 2 VHD, underlining need for further attention on this patient group.
No takes yet. Share an insight, caveat, or question.
Melgaard et al. (2020) conducted a cohort in Atrial Fibrillation with Valvular Heart Disease (n=28,770). Valvular heart disease classification (EHRA Type 1 and Type 2) and anticoagulation status was evaluated on Thromboembolism (ischemic stroke or systemic embolism) and major bleeding at 1 year. EHRA Type 1 and Type 2 VHD carry markedly different risks of thromboembolism and major bleeding, and a significant proportion of high-risk patients are not treated with oral anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: